Targeting the CaN/FoxO1/FABP4 Pathway in Atherosclerosis: Insights from SERCA2 Dysfunction Models

Study Background and Research Question

Atherosclerosis is a multifactorial, chronic inflammatory disorder characterized by the accumulation of lipid-rich plaques in arterial walls, contributing to major cardiovascular events such as myocardial infarction and stroke. Central to plaque progression is the formation of macrophage-derived foam cells, which results from excessive uptake and esterification of modified lipids by macrophages. Recent evidence implicates endoplasmic reticulum (ER) stress and dysregulated lipid metabolism as critical drivers of foam cell formation. The sarcoplasmic/endoplasmic reticulum Ca²⁺ ATPase 2 (SERCA2) enzyme plays a crucial role in maintaining calcium homeostasis and ER function. Loss-of-function mutations, notably the C674S substitution, induce sustained ER stress and inflammation in vascular cells. However, the precise molecular cascade linking SERCA2 dysfunction to foam cell formation and atherosclerosis has remained incompletely understood. This study probes whether SERCA2 dysfunction exacerbates atherosclerosis via disruption of fatty acid metabolic pathways, focusing on the role of the calcineurin (CaN)/forkhead box O1 (FoxO1)/fatty acid binding protein 4 (FABP4) signaling axis (paper).

Key Innovation from the Reference Study

The central innovation of this research lies in elucidating a mechanistic pathway whereby SERCA2 dysfunction augments atherosclerosis risk. Specifically, the study demonstrates that the C674S mutation in SERCA2 upregulates CaN activity, which in turn promotes nuclear translocation of FoxO1 and subsequent transcriptional activation of FABP4. This signaling axis triggers dysregulated fatty acid synthesis, enhanced lipid uptake, and foam cell formation. Crucially, the authors show that pharmacological inhibition of FoxO1 or FABP4, or partial loss of FABP4 function, corrects these metabolic disturbances and mitigates atherosclerotic lesion progression (paper). This work positions FABP4 as a key downstream effector linking SERCA2 dysfunction to macrophage lipid overload and highlights the therapeutic potential of selective FABP4 inhibition in atherosclerosis.

Methods and Experimental Design Insights

The investigators employed a combination of genetic, cellular, and biochemical approaches:

• Animal Models: Heterozygous SERCA2 C674S knock-in (SKI) mice were generated to model SERCA2 dysfunction under pathophysiological conditions.
• Metabolomics: Serum from SKI and wild-type littermates was analyzed to assess systemic metabolic changes.
• Histology: The aorta and aortic root of mice were examined for atherosclerotic lesion area and composition.
• Cellular Studies: Bone marrow-derived macrophages (BMDMs) from SKI and control mice were isolated for protein expression profiling, lipid uptake assays, and foam cell quantification.
• Pharmacological Interventions: Inhibitors of FoxO1 (AS1842856) and FABP4 (BMS 309403) were used to dissect pathway contributions.
• Genetic Approaches: FABP4 partial deficiency was induced to validate its functional necessity in the pathway.

This integrated methodology allowed for comprehensive interrogation of molecular, cellular, and organismal phenotypes linked to SERCA2 dysfunction.

Core Findings and Why They Matter

The study yielded several key findings:

• SERCA2 C674S mutation induces CaN activity and FoxO1 nuclear translocation. This leads to upregulation of FABP4 in BMDMs, linking SERCA2 dysfunction to a specific signaling cascade (paper).
• FABP4 upregulation drives foam cell formation. SKI BMDMs exhibited increased fatty acid synthesis, cholesterol esterification, and lipid droplet accumulation. Metabolomic profiling revealed pronounced disturbances in serum lipid signatures.
• Inhibition of the CaN/FoxO1/FABP4 axis normalizes lipid metabolism and reduces foam cell formation. Both pharmacological FABP4 inhibition (using BMS 309403) and partial FABP4 gene knockout significantly attenuated lipid accumulation in macrophages and reduced atherosclerotic lesion burden in vivo (paper).
• Therapeutic Implication: These data underscore the pathogenic role of the CaN/FoxO1/FABP4 pathway in atherosclerosis, positioning FABP4 inhibition as a promising strategy for intervention, especially in the context of SERCA2-dependent ER stress and metabolic dysregulation.

This mechanistic insight links cellular calcium handling, ER stress, and lipid metabolic control in the context of vascular inflammation, advancing the molecular understanding of atherosclerosis pathogenesis.

Protocol Parameters

• in vitro BMDM foam cell assay | 1–25 μM (BMS 309403) | selective inhibition of FABP4-mediated lipid uptake | Range reflects doses effective for reducing MCP-1 secretion and foam cell formation in macrophages | product_spec
• in vivo atherosclerosis model (ApoE^−/− mice) | chronic administration, dose not specified in paper | evaluating atheroprotective effects of FABP4 inhibition | Used to assess lesion burden and metabolic correction | paper
• stock solution preparation | ≥18.15 mg/mL in DMSO; store at −20°C | ensures solubility and stability for experimental use | DMSO is compatible with cell-based assays; long-term stability requires cold storage | product_spec
• cell culture working concentration | 1–25 μM | BMDM, THP-1 macrophages | Effective range for in vitro FABP4 inhibition and inflammation assays | product_spec

Limitations and Transferability

While the study provides compelling evidence linking the CaN/FoxO1/FABP4 axis to atherogenesis, several aspects limit direct clinical translation:

• The SKI mouse model recapitulates pathological SERCA2 dysfunction but may not capture all facets of human atherosclerosis or the diversity of ER stress responses in patients.
• Pharmacological modulation of FABP4, while effective in cell and animal models, requires further validation regarding long-term safety, off-target effects, and tissue specificity in larger mammals or clinical settings.
• Dose and route optimization for FABP4 inhibitors in chronic disease contexts remain to be established (workflow_recommendation).

Nonetheless, the demonstration that inhibition of a single node (FABP4) in the CaN/FoxO1/FABP4 axis can reverse key disease manifestations highlights its potential as a targeted intervention strategy.

Comparison with Existing Internal Articles

At present, there are no directly relevant internal articles that address the mechanistic role of the CaN/FoxO1/FABP4 pathway or SERCA2 dysfunction in atherosclerosis. Future content development focusing on the intersection of ER stress, lipid metabolism, and vascular inflammation may provide complementary perspectives and workflow optimizations for research teams.

Research Support Resources

Researchers investigating the role of FABP4 in lipid metabolism, inflammation, or disease models such as atherosclerosis and type 2 diabetes can leverage commercially available inhibitors to reproduce and extend these experimental findings. For example, BMS 309403 (SKU B7794) is a potent and selective FABP4 inhibitor, DMSO-soluble, and validated for use in both in vitro and in vivo settings (product_spec). The compound is recommended at concentrations ranging from 1 to 25 μM for cell-based assays, and is suitable for studies exploring FABP4's role in metabolic diseases, inflammation, and cardiovascular disorders. When designing such experiments, adherence to optimal solubility and storage parameters is advised to maintain compound integrity and experimental reproducibility. APExBIO provides detailed technical specifications to assist in protocol development for FABP4 inhibition workflows.